Domo: Despite Near-Term Tailwinds, No Long-Term Durability

Domo, Inc. is rated a Sell as its core business faces existential risk from agentic AI. Learn more about DOMO stock here.

Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market

Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and ...